FDA 483 - Gland Pharma Limited - May 16, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Gland Pharma Limited, a parenteral drug manufacturer, revealed significant deficiencies across multiple areas. The firm failed to adequately investigate unexplained discrepancies, including visible foreign materials in drug products and issues with unclean glassware. Additionally, the inspection identified shortcomings in aseptic processing environmental monitoring, equipment cleaning and sanitization procedures, and contamination control during material transfers.
ID · 4fa4ef18-c157-4399-965f-8e1c149ad245